Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Melanoma 1Lymphoma, Mantle-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Ipilimumab 106Nivolumab 101pembrolizumab 90aldesleukin 72Cyclophosphamide 46Interleukin-2 45Temozolomide 36Dacarbazine 32trametinib 31dabrafenib 30fludarabine phosphate 29incomplete Freund's adjuvant 27Bevacizumab 26sargramostim 25Vemurafenib 25fludarabine 22binimetinib 21Radiosurgery 21Paclitaxel 20encorafenib 19Carboplatin 19CTLA-4 Antigen 18cobimetinib 16atezolizumab 15Radiotherapy 14Biopsy 14Sorafenib 13MART-1 Antigen 12talimogene laherparepvec 11montanide ISA 51 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Melanoma × dinaciclib × Clear all
NCT00937937 2026-05-29

Dinaciclib in Treating Patients With Stage IV Melanoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
72 enrolled 14 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡